Qualified Donor Standard. Implemented 1997 Revised Version 3.0

Similar documents
IQPP Qualified Donor Standard

Quality Assurance Standard. Implemented 1991 Revised Version 3.0

QSEAL Recovered Plasma Specification

Source Plasma Safety

Please find enclosed Dosimetry Service Licence No which replaces Dosimetry Service Licence No

15. Procuring, processing and transporting gametes and

Practice Direction Standard of Practice # 5: Administration of Drugs including Vaccines

This follows similar work previously conducted by Bureau Veritas for Nestlé S.A. in other global operations.

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

Guidance for Industry

TERMS AND CONDITIONS NATIONAL GOOD LABORATORY PRACTICE (GLP) COMPLIANCE MONITORING AUTHORITY

LAB5 EDITION 2 NOVEMBER 2012

PFC Industry Courses and Certifications

UKAS Guidance on the Application of ISO/IEC Dealing with Expressions of Opinions and Interpretations

Committed to Environment, Health and Safety

Availability of FSIS Compliance Guidelines for Allergens and. Ingredients of Public Health Concern: Identification, Prevention

MIAMI CHILDREN S HOSPITAL POLICY AND PROCEDURE

Human Research Participant Protection Program

Falsified Medicines Directive - Safety Features Update

Guidance for Industry

Darwin Marine Supply Base HSEQ Quality Management Plan

APPENDIX 1 State Summary Tables

Washoe County Medical Marijuana Establishment Business License Common Questions

CTO Establishment Inspections. an Atlantic update - Tissues

LEAF Marque Chain of Custody Self Assessment v1.0 Downloadable Copy A

Basis for Conclusions: ISA 230 (Redrafted), Audit Documentation

A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:

PFC Training Courses & Programs. Course Descriptions. 1. Core Cannabis Training (CCT) [pre-requisite for all PFC Courses]

City of Carson 701 E. Carson St., Carson, CA Telephone: (310) ; ci.carson.ca.us

Executive Summary for Executive Licensing Panel 20 May Dr Kamal Ahuja. Follow-up inspection 14 April 2010

TGA regulation of local manufacturers of plasma derivatives CSL Behring Australia s overview

Public manual: Application for permission of a product and correction of permitted items: for food for weight control person Service agency:

Guidance for Industry

Food Safety Modernization Act - Impacts on the Grain and Feed Industry

How To Document Length of Time Homeless in WISP

GMP IN BLOOD ESTABLISHMENTS: A BASIC ELEMENT FOR PLASMA QUALITY

SCOTIABANK ANTI-MONEY LAUNDERING (AML) / ANTI-TERRORIST FINANCING (ATF) QUESTIONNAIRE

General Concepts in the European Pharmacopoeia. Anne-Sophie Bouin European Pharmacopoeia Department, EDQM, Council of Europe

Plasma for fractionation: South African Plasma Requirements

Guidance for Industry

July 27-30, th Annual Meeting of the Poultry Science Association Louisville, Kentucky. Presented at:

EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY

STAFF REPORT City of Lancaster NB 2

Welcome to presentation By Sanjay Punjabi Lead Auditor for ISO 9001, ISO 14001, OHSAS & BS 7799

AGREEMENT ON COMMON PRINCIPLES AND RULES OF CIRCULATION OF MEDICINAL PRODUCTS WITHIN THE EURASIAN ECONOMIC UNION. (Moscow, 23 December 2014)

FDA Food Safety Modernization Act (FSMA) January 4, 2011

Foreign Supplier Verification Programs for Importers of Food for Humans and Animals

N.J.A.C. 8:8-1 et seq.

NJ CBCT Regulation FAQ & Assistance

DEPARTMENT OF HEALTH AND SENIOR SERVICES PO BOX 360 TRENTON, N.J

MUNICIPAL COUNCIL OF THE CITY OF BAYONNE

AN EMPLOYERS GUIDE TO NDT PERSONNEL CERTIFICATION

Committed to Environment, Health, & Safety

New Mexico Administrative Office of the Courts Language Access Services 237 Don Gaspar, Room 25 Santa Fe, New Mexico 87504

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

IAASB Main Agenda (March 2005) Page Agenda Item. DRAFT EXPLANATORY MEMORANDUM ISA 701 and ISA 702 Exposure Drafts February 2005

Type 2 Diabetes Risk Awareness Event

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

Performance Audit. Department of Health and Human Services Division of Public and Behavioral Health Medical Marijuana Program 2017

HIV Rules & Statutes:

Pennsylvania s Medical Marijuana Program

Guidance for Industry

(4) Be as detailed as necessary to provide history of work performed; and:

IAF Mandatory Document. Requirements for the Migration to ISO 45001:2018 from OHSAS 18001:2007 (IAF MD 21:2018)

Proposal to Modify ABO Determination, Reporting, and Verifications Requirements. Operations and Safety Committee June 2015

Environmental Health and Safety. Hearing Conservation Program

BMA INFORMATION BULLETIN No. 23. International Safety Management (ISM) Code

MDEP VICWG-02. Technical Report

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

[Submitted Electronically]

UNITED ARAB EMIRATES

CHAPTER 64B5-12 CONTINUING PROFESSIONAL EDUCATION

Organ Procurement and Transplantation Network

QA Regulatory forum: Classification and Risk assessment according to MDR Date : T h e r e s e. A l b i n s s o m e d q t e c h.

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Sharing of EP 200 Inspection Findings

Healthy Eating for Gestational Diabetes SERVICE PROJECT PLANNER

Standard Operating Procedures (SOP) Research and Development Office

PHYSIOTHERAPY ACT AUTHORIZATION REGULATIONS

23 November Division of Dockets Management (HFA 305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852

COMMUNITY HOSPICE & PALLIATIVE CARE NOTICE OF PRIVACY PRACTICES

Sterilization of health care products Radiation. Part 3: Guidance on dosimetric aspects of development, validation and routine control

ANSI/ASNT CP-189 Inquiries

Application for Ethical Approval of Research Proposals

NJ RAPID HIV TESTING SUPPORT PROGRAM

New Markets Tax Credit CDE Certification Question & Answer

Quality Management Aspects of Sperm and Testicular Tissue Cryobanking

Non-Prescription Medicinal Products Containing Codeine: Guidance for Pharmacists on Safe Supply to Patients

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business

RECALL / EVENT INVESTIGATION & PATIENT LOOK BACK

ORDINANCE NO

Medical Devices. BARBADOS Clarke Gittens Farmer

ORDINANCE (Next in Line)

Oral Health Assessment Handbook

SOP-QA-30 V Scope

South Carolina General Assembly 122nd Session,

Responsible Retailing of Recreational Cannabis. Recommendations to British Columbia s Cannabis Regulation Engagement Secretariat

INDUSTRIAL WASTEWATER PERMIT APPLICATION (SHORT FORM DENTAL OFFICE OR CLINIC)

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 2760

APPENDIX B: MEDICAL POLICY STATEMENTS

Transcription:

Implemented 1997 Revised 2006 Version 3.0

IQPP Contents I. Background... 3 II. Definitions... 3 III. Standard... 3 IV. Inspection and Compliance Verification... 4 Appendix 1: Questions & Answers... 5 Page 2

IQPP I. Background The purpose of the standard is to take advantage of opportunities in the collection and processing of plasma for further manufacture into therapeutic plasma products to further reduce the risk of undetected infectious units of plasma being manufactured. The standard attempts to exclude from manufacture window units by requiring additional testing/donations to qualify Applicant Donors. II. Definitions Applicant Donor - Qualified Donor - All individuals presenting themselves who have not been previously qualified as a donor within the past six (6) months. All individuals who have been qualified for continued donations by successfully passing two donor medical history screenings and required viral testing. III. Standard Individuals will be considered Applicant Donors until they have successfully passed the following two-stage minimum donor screening process: 1. Persons presenting themselves for donation initially will be screened according to all applicable regulatory and IQPP screening and testing criteria. This applies whether a complete plasma unit or blood/plasma sample only is collected. At this stage the person will be considered an Applicant Donor. The initial screening required by IQPP of Applicant Donors include: a. Physical examination by a Physician or Physician Substitute; b. Check against the National Donor Deferral Registry (NDDR); c. Donor education and quiz on high-risk activities. Page 3

2. Reclassification of a person from Applicant Donor to Qualified Donor is achieved by passing the physical examination as required by regulations and: a. Subsequent donation of a complete unit and donor screening and testing based on all applicable regulatory and IQPP requirements noted above; or b. Subsequent donation of a sample only and donor screening and testing based on all applicable regulatory and IQPP requirements noted above. The subsequent screening of Applicant Donors must occur no less than the minimum time interval allowed by applicable regulatory requirements and no greater than six (6) months. Testing and donor screening to classify a person as a Qualified Donor must be administered by plasma centers operated by the same company. No units of plasma from Applicant Donors will be acceptable for the manufacture of therapeutic plasma products until the person has become a Qualified Donor. Donations made by Applicant Donors who do not return to become Qualified Donors shall be clearly labeled in accordance with the requirements of the relevant health authority for non-injectable use only or destroyed. IV. Inspection and Compliance Verification Auditors shall request the plasma center s procedures or system for managing Applicant Donors. They shall then track through the documentation of several donors/units for compliance. The plasma center s owners, upon IQPP certification or recertification, must sign a statement that all donors will be processed in accordance with the definitions for Applicant and Qualified donors and the standard above. Page 4

IQPP Appendix 1: Questions & Answers Related to IQPP The questions and answers below are intended to help clarify the International Quality Plasma Program QUALIFIED DONOR STANDARD. Q. Can you prescreen a donor without collecting a unit of plasma? A. The Applicant Donor must undergo a complete donor testing and medical screening on the initial visit, whether a unit of plasma is collected or only a blood/plasma sample. This is not intended to preclude the practice of using a government approved infrequent donor program screening process (i.e., it does not necessarily require that a physician perform physical examination and screening unless regulations would require it). Q. Can you collect a sample only subsequent to the initial visit and donor screening in order to qualify the donor or unit? A. Following the initial Applicant Donor screening and testing, the donor must successfully pass all the donor health history screening interview questions and viral marker testing whether or not a unit of plasma is drawn. Since a complete unit is not being collected and this sample and screening only would be as a part of the IQPP Standard, it would not be necessary to perform the various donor vital signs screening tests such as hematocrit. Q. Must you have completed the testing from the original Applicant Donor visit prior to accepting a subsequent donation? A. No. But, it must be completed prior to acceptance of the unit for further manufacturing as required by regulatory authorities. Q. What is the minimum and maximum time period between viral marker testing for Applicant Donors? A. Donations or test samples and donor screening procedures must be done no more frequently than the minimum time interval between donations allowed by the applicable regulatory authority. Additionally, those individuals not appearing for donation for greater than six (6) months will be considered Applicant Donors and must be re-qualified to become classified as a Qualified Donor. Page 5

Q. Can a donor be reclassified as an Applicant donor at an interval of less than six months? A. Companies are entitled to make the more rigorous by reclassifying donors as Applicants following an interdonation interval of less than six months. However, they must comply with the requirements of the and treat the donors and the units as Applicant and these policies must be reflected in the company's SOPs. In addition, when submitting viral marker data according to the Viral Marker Standard, the IQPP definitions of Applicant and Qualified must be adhered to. Q. Can test results from previous or subsequent donations at other licensed collection facilities be used to qualify a donor? A. No. However, if the test results and other required donor screening information is administered by a plasma center operated by the same company, it would be acceptable. This would not preclude the use of test results performed by a separate laboratory specifically for that plasma center (i.e., testing performed by the fractionator customer s laboratory for the plasma center). Q. How is the status of Applicant Donors who have not yet returned to become Qualified Donors affected by a change in ownership of the plasma center and donor screening/test information? A. It is not affected. Although technically the donor screening and testing information from the two donation visits necessary to qualify a donor would be administered and owned by two different legal entities, it is interpreted by IQPP as the consistent property of the plasma center. Page 6

IQPP Revision History Date Version History November 1997 1.0 Standard implemented. May 2000 2.0 Added Appendix: Q&A April 2006 3.0 January 2013 3.0 Document format change ONLY Page 7